Skip to main content
. 2020 Feb 6;111(2):571–579. doi: 10.1111/cas.14265

Table 2.

Treatment‐related treatment‐emergent adverse events (occurring in ≥10% of the total study population)

Preferred terma 1‐30 mg (n = 12) 60 mg (n = 3) 100 mg (n = 3) 140 mg (n = 3) 180 mg (n = 3) Total (N = 24)
Any grade ≥Grade 3 Any grade ≥Grade 3 Any grade ≥Grade 3 Any grade ≥Grade 3 Any grade ≥Grade 3 Any grade ≥Grade 3
Blood creatinine increased 2 (16.7) 2 (66.7) 1 (33.3) 3 (100.0) 1 (33.3) 9 (37.5)
Hyperphosphatemia 3 (100.0) 3 (100.0) 3 (100.0) 9 (37.5)
ALT increased 1 (33.3) 3 (100.0) 2 (66.7) 2 (66.7) 6 (25.0) 2 (8.3)
Diarrhea 2 (66.7) 1 (33.3) 3 (100.0) 6 (25.0)
Lipase increased 1 (8.3) 1 (33.3) 1 (33.3) 1 (33.3) 1 (33.3) 5 (20.8)
Nausea 1 (8.3) 1 (33.3) 1 (33.3) 1 (33.3) 1 (33.3) 5 (20.8)
AST increased 2 (66.7) 2 (66.7) 1 (33.3) 4 (16.7) 1 (4.2)
PPE syndrome 1 (33.3) 1 (33.3) 2 (66.7) 4 (16.7)
Anemia 1 (33.3) 1 (33.3) 1 (33.3) 3 (12.5)
Blood ALP increased 1 (33.3) 2 (66.7) 3 (12.5)
Dysgeusia 2 (66.7) 1 (33.3) 3 (12.5)
Retinal detachment 2 (66.7) 1 (33.3) 3 (12.5)
Vomiting 1 (33.3) 1 (33.3) 1 (33.3) 1 (33.3) 3 (12.5) 1 (4.2)

Values are shown as n (%); percentages are based on the number of treated patients in the relevant treatment cohort.

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PPE, palmar‐plantar erythrodysesthesia; –, no incidence.

a

Coded using the Medical Dictionary for Regulatory Activities, version 20.1.